Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Diagnostic Biomarkers Market Forecast: What Market Value Is Expected By 2030?
The diagnostic biomarkers market experienced substantial expansion recently, projected to increase from $75.46 billion in 2025 to $87.47 billion in 2026, reflecting a compound annual growth rate (CAGR) of 15.9%. This past period of growth was fueled by advancements in molecular diagnostics, increased investment in cancer research, the inherent limitations of conventional diagnostic methods, a growing prevalence of chronic diseases, and ongoing biomarker validation initiatives.
The market for diagnostic biomarkers is poised for substantial expansion in the coming years, projected to reach $155.92 billion by 2030, reflecting a compound annual growth rate (CAGR) of 15.5%. This projected increase during the forecast period is driven by several key factors, including progress in omics technologies, the burgeoning field of personalized medicine, artificial intelligence-powered biomarker discovery, the approval of innovative biomarkers by regulatory bodies, and a heightened need for predictive diagnostic tools. Furthermore, significant trends shaping this market over the forecast period involve the increasing acceptance of precision diagnostic biomarkers, a greater utilization of both genomic and proteomic biomarkers, the expanding application of biomarkers within oncology diagnostics, the incorporation of biomarker data into clinical analytics, and a continuous rise in the demand for early disease detection methods.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21171&type=smp
Diagnostic Biomarkers Market Expansion Supported By Key Demand Factors
The increasing incidence of cancer is a significant catalyst for the expansion of the diagnostic biomarkers market. This rise in cancer cases is attributable to several contributing elements, including an aging global population, evolving lifestyle habits, exposure to environmental factors, and advancements in diagnostic technologies. Within the realm of cancer management, diagnostic biomarkers are instrumental, facilitating prompt identification, accurate diagnosis, and tailored therapeutic approaches that ultimately lead to better patient prognoses. For example, data from the American Cancer Society, a prominent US non-profit organization dedicated to cancer advocacy, indicated a rise in cancer diagnoses from 1,958,310 in 2023 to 2,001,140 in January 2024, signifying a 2.19% increase. Consequently, this escalating prevalence of cancer is propelling the diagnostic biomarkers market forward.
Diagnostic Biomarkers Market Segment Outlook: Which Categories Are Expanding The Fastest?
The diagnostic biomarkers market covered in this report is segmented –
1) By Product: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers
2) By Application: Oncology, Metabolic Disease, Neurological Disease
3) By End User: Hospitals, Cancer Research Institutes, Diagnostic Labs
Subsegments:
1) By Safety Biomarkers: Toxicity Biomarkers, Organ-Specific Safety Biomarkers, Drug-Induced Injury Biomarkers
2) By Efficacy Biomarkers: Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers
3) By Validation Biomarkers: Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers
Diagnostic Biomarkers Market Growth Trends Influencing Competitive Dynamics
Leading corporations within the diagnostic biomarkers sector are prioritizing the creation of less invasive analytical techniques, exemplified by blood-based biomarker assays, with the goals of improving patient experience and facilitating customized therapeutic approaches. A blood-based biomarker assay functions as a diagnostic instrument that examines particular biological indicators present in blood samples to identify or track illnesses, including Alzheimer’s disease, through a procedure that involves minimal bodily intrusion. For illustration, in July of 2023, Quanterix Corporation, a United States entity operating in the life sciences domain, introduced LucentAD, a blood assay intended to aid medical practitioners in identifying Alzheimer’s disease (AD) in individuals presenting with initial signs of cognitive decline. This assay quantifies the concentration of phosphorylated tau protein at the 181 amino acid position (p-Tau 181) in plasma, which serves as a biological marker linked to the accumulation of amyloid plaques in the brain, a crucial diagnostic sign of AD. Offering a more patient-friendly and easily accessible method of diagnosis than conventional procedures such as cerebrospinal fluid examination or amyloid positron emission tomography, LucentAD seeks to simplify the diagnostic pathway for individuals suspected of having Alzheimer’s.
Diagnostic Biomarkers Market Key Companies And Competitive Benchmarking
Major companies operating in the diagnostic biomarkers market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, PerkinElmer Inc., Siemens Healthineers AG, Merck KGaA, Agilent Technologies Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., Myriad Genetics Inc., Meso Scale Diagnostics LLC, EKF Diagnostics Holdings Plc, Sino Biological Inc., Enzo Biochem Inc., Biomarker Technologies Inc., Cisbio Bioassays, Signosis Inc., Epigenomics AG, LifeSign LLC, Banyan Biomarkers Inc., Biosims Technologies SAS
Access The Complete Diagnostic Biomarkers Market Report:
https://www.thebusinessresearchcompany.com/report/diagnostic-biomarkers-global-market-report
Diagnostic Biomarkers Market Geographic Distribution And Regional Opportunities
North Americawas the largest region in the diagnostic biomarkers market in 2025. The regions covered in the diagnostic biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
